Format

Send to

Choose Destination
Tidsskr Nor Laegeforen. 2009 Aug 27;129(16):1631-4. doi: 10.4045/tidsskr.09.35501.

[Myositis-specific autoantibodies].

[Article in Norwegian]

Author information

1
Revmatologisk avdeling, Oslo universitetssykehus, Rikshospitalet, 0027 Oslo, Norway. jan.tore.gran@rikshospitalet.no

Abstract

BACKGROUND:

Myositis-specific antibodies (MSA) are autoantibodies that are almost exclusively detected in idiopathic inflammatory myopathies (IIM). This article provides an overview of these autoantibodies and how they can be used clinically to identify subgroups of IIM.

MATERIAL AND METHODS:

The article is based on a non-systematic literature review and our own experience.

RESULTS:

MSA can be detected in up to 50 % of patients with IIM. Patients with anti-synthetase antibodies have a constellation of clinical findings termed "the anti-synthetase syndrome", in which interstitial lung disease dominates the clinical picture. Anti-Mi2 antibodies is another myositis-specific antibody. Patients with anti-Mi2 antibodies often have classical dermatomyositis, while the anti-SRP antibody identifies patients with severe myopathy, poor response to treatment with corticosteroids and histological findings of muscle cell necrosis - often lacking inflammatory infiltrates. The newly detected anti-CADMp140 appears to be associated with amyopathic or hypomyopathic dermatomyositis, previously called dermatomyositis sine myositis. Anti-p155 antibodies are most often found in patients who also have cancer.

INTERPRETATION:

Myositis-specific antibodies may be useful for identification of clinical subgroups of IIM and can thereby affect the choice of medical treatment.

PMID:
19721478
DOI:
10.4045/tidsskr.09.35501
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Norwegian Medical Association Icon for Norwegian BIBSYS system
Loading ...
Support Center